Group 1 - Dawn Health has secured EUR 11.5 million in funding from existing investors to scale its platform and product suite for next-generation pharmaceutical digital health solutions [1] - The company has developed a platform tailored for the pharmaceutical industry, which has been adopted by major players like Merck and Novartis [2] - The Dawn Platform enhances patient care and outcomes through advanced capabilities in AI, data analytics, and clinical integrations, supporting therapy companions and disease management programs [3] Group 2 - The CEO of Dawn Health emphasized the ambition to lead in digital health and improve patient lives globally, with the new funding aimed at expanding market reach [4] - Since a major investment in December 2021, Dawn Health has significantly increased its revenue and workforce, now employing over 100 people [5] - Dawn Health specializes in Software as a Medical Device (SaMD) and Digital Therapeutics (DTx), focusing on chronic conditions and patient-centric solutions [6]

SAN FRANCISCO, May 01, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months ended March 31, 2025. First Quarter 2025 Financial Highlights Revenue of $158.7 million, a 20.3% increase compared to first quarter 2024Gross margin of 68.8%, a 250-basis point increase compared to first quarter 2024Unrestricted cash, cash equivale ...

Company Overview - PAVmed Inc. is a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors [4] - The company has two subsidiaries: Lucid Diagnostics, which focuses on cancer prevention diagnostics, and Veris Health, which enhances personalized cancer care through remote patient monitoring [4] Upcoming Conference Call - PAVmed will host a business update conference call and webcast on May 15, 2025, at 8:30 AM ET [1] - The call will feature Lishan Aklog, M.D., providing an overview of the company's operations and growth strategy, and Dennis McGrath discussing the first quarter 2025 financial results [1] Access Information - The webcast will be available on the investor relations section of the company's website [2] - U.S.-based callers can join the conference call by dialing 1-800-836-8184, while international listeners should dial 1-646-357-8785 [2] Replay Availability - A replay of the conference call will be available for 30 days on the investor relations section of the company's website [3]

Core Viewpoint - iRhythm Technologies, Inc. is actively participating in the Bank of America Securities 2025 Health Care Conference, showcasing its commitment to advancing digital health solutions [1][2]. Company Overview - iRhythm Technologies, Inc. is a leading digital health care company focused on creating solutions that detect, predict, and prevent disease through the use of wearable biosensors and cloud-based data analytics [3]. - The company utilizes proprietary algorithms to transform data from millions of heartbeats into clinically actionable information, aiming to enhance patient care and health outcomes [3]. Event Participation - iRhythm's management is scheduled to present at the conference on May 13, 2025, at 3:40 p.m. Pacific Time, with a live and archived webcast available for interested parties [2].

OCTOPUS TITAN VCT PLC Annual report and financial statements for the year ended 31 December 2024 Octopus Titan VCT plc announces the final results for the year to 31 December 2024 as below. Octopus Titan VCT plc (‘Titan’ or the ‘Company’) is managed by Octopus AIF Management Limited (the ‘Manager’), which has delegated investment management to Octopus Investments Limited (‘Octopus’ or ‘Portfolio Manager’) via its investment team Octopus Ventures. Key financials 20242023Net assets (£’000)£831,358£993,744Los ...

Group 1 - The transaction of MRI imaging data assets in Fuzhou marks the first instance of medical data asset usage fees being collected into the national treasury, indicating a successful implementation of the entire process from inventory, registration, pricing, authorized operation to data asset trading [1] - The total transaction amount was 9,759 yuan, involving over 100 cases of brain MRI imaging data, purchased by Fuzhou Data Technology Research Institute Co., Ltd. The data was strictly anonymized to ensure personal information could not be traced back [1] - The medical data assets are primarily intended for the development of a digital jaw precision positioning system, highlighting the significance of health data in enhancing medical standards [1] Group 2 - Fuzhou has been a pilot city for the construction of national health medical big data centers since 2016, with continuous integration of health data into the regulatory platform covering 261 public hospitals and community institutions in the province [2] - The platform is expected to complete the collection and aggregation of over 200 billion medical data entries by October this year, with 20 billion entries already governed [2] - The establishment of a "trusted data space" within the government cloud aims to ensure that all data usage processes are completed securely, allowing for the development of AI models without exposing original data [2] Group 3 - The transaction is expected to activate the value of medical data assets, attracting AI medical enterprises and data service providers to collaborate, which will drive the value of the entire industry chain [3] - Fuzhou New Area aims to enhance the data asset management system and promote cross-regional data asset integration, striving to create a national hub for the circulation of medical data assets [3] - The focus is on efficient allocation and widespread application of medical data assets, fostering a more vibrant digital medical industry ecosystem [3]

NEW YORK, April 21, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) ("Dario" or the "Company"), a leading global digital health company, today announced that Zvi Ben-David, Chief Financial Officer, will retire from his role, effective May 15, 2025. The Company has appointed Chen Franco-Yehuda as its new Chief Financial Officer, Treasurer, and Secretary, and will assume the role upon Mr. Ben-David's retirement on May 15, 2025. To ensure a smooth transition, Mr. Ben-David will remain with the Company un ...

Core Viewpoint - iRhythm Technologies, Inc. will release its financial results for Q1 2025 on May 1, 2025, followed by a conference call to discuss the results [1]. Company Overview - iRhythm Technologies is a leading digital health care company focused on creating solutions that detect, predict, and prevent disease [3]. - The company utilizes wearable biosensors and cloud-based data analytics combined with proprietary algorithms to transform data from millions of heartbeats into clinically actionable information [3]. - iRhythm's vision emphasizes improving patient care through better data, insights, and health outcomes [3]. Conference Call Details - The conference call will begin at 1:30 p.m. PT / 4:30 p.m. ET on the same day as the financial results release [1]. - Interested parties can access a live and archived webcast of the conference call on the company's investor website [2].

Core Insights - Transcarent has completed the acquisition of Accolade for approximately $621 million, enhancing its digital health offerings [1][2] - Accolade shareholders received $7.03 per share in cash, and the company's stock will no longer be traded on Nasdaq [2] - Transcarent aims to create a new health and care experience by integrating Accolade's capabilities, emphasizing the benefits of their combined resources [3] Company Overview - Transcarent provides at-risk pricing models to self-insured employers, facilitating quick access to care and benefits navigation for employees [3] - As of May, Transcarent has raised around $450 million, achieving a valuation of $2.2 billion [3] - The company was recognized on CNBC's Disruptor 50 list last year, highlighting its innovative approach in the digital health sector [3]

Core Insights - Biotricity Inc. has been recognized as one of The Americas' Fastest-Growing Companies 2025 by the Financial Times, achieving a remarkable growth rate of 256.4% during challenging global conditions [1][2][3] Company Performance - The evaluation by the Financial Times, in collaboration with Statista, focused on independent companies across the Americas based on revenue growth from 2020 to 2023, amidst significant economic challenges such as the COVID-19 pandemic and supply chain disruptions [2] - Biotricity's growth is attributed to the increasing demand for smart remote monitoring solutions, addressing the needs of over 100 million Americans who face barriers to essential healthcare services [3] Innovation and Market Position - Biotricity is at the forefront of transforming healthcare with proprietary technologies that enhance continuous remote monitoring for high-risk cardiac patients, enabling medical providers to deliver faster interventions and improve patient outcomes [3] - The company's mission to revolutionize chronic care management, particularly in the cardiac sector, is gaining momentum, as highlighted by the recognition from the Financial Times [4]